Ensysce Biosciences (Ensysce Biosciences) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Ensysce Biosciences is: No Data: Cannot be evaluated.

Competitive Comparison of Ensysce Biosciences's Risk Assessment

For the Biotechnology subindustry, Ensysce Biosciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensysce Biosciences's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Risk Assessment falls into.

Ensysce Biosciences (NAS:ENSC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Ensysce Biosciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensysce Biosciences (Ensysce Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037

Website

https://www.ensysce.com

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.

Executives

Bob G Gower	director	402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick	director, officer: Chief Executive Officer	110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman	officer: Chief Medical Officer	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch	director	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano	officer: Chief Development Officer	7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett	officer: Chief Commercial Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt	officer: Chief Medical Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey	officer: Chief Financial Officer	4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang	director, 10 percent owner	C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard	officer: Chief Operating Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright	officer: Chief Business Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin	director	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037